Demonstration of sustained drug-resistant human immunodeficiency virus type 1 lineages circulating among treatment-naive individuals

Journal of Virology

Volumn 83, Issue 6, 2009, Pages 2645-2654

  Hué, Stephane ^a,e   Gifford, Robert J ^b,e   Dunn, David ^c,e   Fernhill, Esther ^c,e   Pillay, Deenan ^a,d,e  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b STANFORD UNIVERSITY   (United States)

^c Medical Research Centre   (United Kingdom)

^d PUBLIC HEALTH ENGLAND   (United Kingdom)

^e Behalf of the UK Collaborative Group on HIV Drug Resistance   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; POL PROTEIN;

ARTICLE; BAYES THEOREM; COHORT ANALYSIS; CROSS RESISTANCE; DEVELOPED COUNTRY; DEVELOPING COUNTRY; DRUG EFFICACY; GENE SEQUENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MONTE CARLO METHOD; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYLOGENY; PRIORITY JOURNAL; STRUCTURAL GENE; TREATMENT PLANNING; UNITED KINGDOM; VIRUS MUTATION; ANTIVIRAL RESISTANCE; CLUSTER ANALYSIS; DISEASE TRANSMISSION; DNA SEQUENCE; DRUG EFFECT; GENETICS; ISOLATION AND PURIFICATION; MOLECULAR GENETICS; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

CLUSTER ANALYSIS; DRUG RESISTANCE, VIRAL; GREAT BRITAIN; HIV INFECTIONS; HIV-1; HUMANS; MALE; MOLECULAR SEQUENCE DATA; PHYLOGENY; POL GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; SEQUENCE ANALYSIS, DNA;

EID: 62749131195     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.01556-08     Document Type: Article

References (51)

1. Brenner, B. G., M. Roger, J. P. Routy, D. Moisi, M. Ntemgwa. C. Matte, J. G. Baril, R. Thomas, D. Rouleau, J. Bruneau, R. Leblanc, M. Legault, C. Tremblay, H. Charest, and M. A. Wainberg. 2007. High rates of forward transmission events after acute/early HIV-1 infection. J. Infect. Dis. 195:951-959.
2. Cane, P., I. Chrystie, D. Dunn, B. Evans, A. M. Geretti, H. Green, A. Phillips, D. Pillay, K. Porter, A. Pozniak, C. Sabin, E. Smit, J. Weber, and M. Zuckerman. 2005. Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ 331:1368.
3. Cane, P. A., H. Green, E. Fearnhill, and D. Dunn. 2007. Identification of accessory mutations associated with high-level resistance in HIV-1 reverse transcriptase. AIDS 21:447-455.
4. Cohen, O. J., and A. S. Fauci. 1999. Transmission of drug-resistant strains of HIV-1: unfortunate, but inevitable. Lancet 354:697-698.
5. Cong, M. E., W. Heneine, and J. G. Garcia-Lerma. 2007. The fitness cost of mutations associated with human immunodeficiency virus type 1 drug resistance is modulated by mutational interactions. J. Virol. 81:3037-3041.
6. de Oliveira, T., K. Deforche, S. Cassol, M. Salminen, D. Paraskevis, C. Seebregts, J. Snoeck, E. J. van Rensburg, A. M. Wensing, D. A. van de Vijver, C. A. Boucher, R. Camacho, and A. M. Vandamme. 2005. An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics. 21:3797-3800.
7. Devereux, H. L., M. Youle, M. A. Johnson, and C. Loveday. 1999. Rapid decline in detectability of HIV-1 drag resistance mutations after stopping therapy. AIDS 13:F123-F127.
8. Drummond, A. J., and A. Rambaut. 2007. BEAST: Bayesian evolutionary analysis by sampling trees. BMC Evol. Biol. 7:214.
9. Egger, M, B. Hirschel, P. Francioli, P. Sudre, M. Wirz, M. Flepp, M. Rickenbach, R. Malinverni, P. Vernazza. and M. Battegay. 1997. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study. BMJ 315:1194-1199.
10. Evering, T. H., and M. Markowitz. 2008. Raltegravir: an integrase inhibitor for HIV-1. Expert Opin. Investig. Drugs 17:413-422.
11. Fan, N., K. B. Rank, D. E. Slade, S. M. Poppe, D. B. Evans, L. A. Kopta, R. A. Olmsted, R. C. Thomas, W. G. Tarpley, and S. K. Sharma. 1996. A drag resistance mutation in the inhibitor binding pocket of human immunodeficiency virus type 1 reverse transcriptase impairs DNA synthesis and RNA degradation. Biochemistry 35:9737-9745.
12. Fitch, W. M. 1971. Toward defining the course of evolution: minimum change for a specific tree topology. Syst. Zool. 20:406-416.
13. Furman, P. A., and D. W. Barry. 1988. Spectrum of antiviral activity and mechanism of action of zidovudine. An overview. Am. J. Med. 85:176-181.
14. Gazzard, B., A. J. Bernard, M. Boffito, D. Churchill, S. Edwards, N. Fisher, A.M. Geretti, M. Johnson, C. Leen, B. Peters, A. Pozniak, J. Ross, J. Walsh, E. Wilkins, and M. Youle. 2006. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006). HIV Med. 7:487-503.
15. Gilford, R. J., T. de Oliveira, A. Rambaut, O. G. Pybus, D. Dunn, A. M. Vandamme, P. Kellam, and D. Pillay. 2007. Phylogenetic surveillance of viral genetic diversity and the evolving molecular epidemiology of human immunodeficiency virus type 1. J. Virol. 81:13050-13056.
16. Harrigan, P. R., S. Bloor, and B. A. Larder. 1998. Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro. J. Virol. 72:3773-3778.
17. Health Protection Agency. 2007. Health protection report, vol. 1, no. 31. Health Protection Agency, London, England. http://www.hpa.org.uk/hpr/ archives/2007/hpr3107.pdf.
18. Health Protection Agency. 2007. Testing times. HIV and other sexually transmitted infections in the United Kingdom: 2007. Health Protection Agency, London, England. http://www.hpa.org.uk/webc/HPAwebFile/HPAweb-C/ 1203496897276.
19. Johnson, V. A., F. Brun-Vezinet, B. Clotet, H. F. Gunthard, D. R. Kuritzkes, D. Pillay, J. M. Schapiro, and D. D. Richman. 2008. Update of the drag resistance mutations in HIV-1: spring 2008. Top. HIV Med. 16:62-68.
20. Keele, B. F., E. E. Giorgi, J. F. Salazar-Gonzalez, J. M. Decker, K. T. Pham, M. G. Salazar, C. Sun, T. Grayson, S. Wang, H. Li, X. Wei, C. Jiang, J. L. Kirchherr, F. Gao, J. A. Anderson, L. H. Ping, R. Swanstrom, G. D. Tomaras, W. A. Blattner, P. A. Goepfert, J. M. Kilby, M. S. Saag, E. L. Delwart, M. P. Busch, M. S. Cohen, D. C. Montefiori, B. F. Haynes, B. Gaschen, G. S. Athreya, H. Y. Lee, N. Wood, C. Seoighe, A. S. Perelson, T. Bhattacharya, B.T. Korber, B. H. Hahn, and G. M. Shaw. 2008. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Natl. Acad. Sci. USA 105:7552-7557.
21. Land, S., K. McGavin, C. Birch, and R. Lucas. 1991. Reversion from zidovudine resistance to sensitivity on cessation of treatment. Lancet 338:830-831.
22. Lataillade, M., J. Chiarella, and M. J. Kozal. 2007. Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance. Antivir. Ther. 12:563-570.
23. Lewis, F., G. J. Hughes, A. Rambaut, A. Pozniak, and A. J. Leigh Brown. 2008. Episodic sexual transmission of HIV revealed by molecular phylody-namics. PLoS Med. 5:e50.
24. Little, S. J., S. D. Frost, J. K. Wong, D. M. Smith, S. L. Pond, C. C. Ignacio, N. T. Parkin, C. J. Petropoulos, and D. D. Richman. 2008. The persistence of transmitted drag resistance among subjects with primary HIV infection. J. Virol. 82:5510-5518.
25. Little, S. J., S. Holte, J. P. Routy, E. S. Daar, M. Markowitz, A. C. Collier, R. A. Koup, J. W. Mellors, E. Connick, B. Conway, M. Kilby, L. Wang, J. M. Whitcomb, N. S. Hellmann, and D. D. Richman. 2002. Antiretroviral-drug resistance among patients recently infected with HIV. N. Engl. J. Med. 347:385-394.
26. Maddison, D. R., and W. P. Maddison. 2001. MacClade 4: analysis of phy-logeny and character evolution, version 4.02. Sinauer Associates, Sunder-land, MA.
27. Melby, T., R. Demasi, N. Cammack, G. D. Miralles, and M. L. Greenberg. 2007. Evolution of genotypic and phenotypic resistance during chronic treatment with the fusion inhibitor T-1249. AIDS Res. Hum. Retrovir. 23:1366-1373.
28. Mocroft, A., B. Ledergerber, C. Katlama, O. Kirk, P. Reiss, A. d'Arminio Monforte, B. Knysz, M. Dietrich, A. N. Phillips, and J. D. Lundgren. 2003. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 362:22-29.
29. Palella, F. J., Jr., K. M. Delaney, A. C. Moorman, M. O. Loveless, J. Fuhrer, G. A. Satten, D. J. Aschman, S. D. Holmberg, et al. 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 338:853-860.
30. Pao, D., M. Fisher, S. Hue, G. Dean, G. Murphy, P. A. Cane, C. A. Sabin, and D. Pillay. 2005. Transmission of HIV-1 during primary infection: relationship to sexual risk and sexually transmitted infections. AIDS 19:85-90.
31. Phillips, A N, C. Leen, A. Wilson, J. Anderson, D. Dunn, A. Schwenk, C. Orkin, T. Hill, M. Fisher, J. Walsh, D. Pillay, L. Bansi, B. Gazzard, P. Easterbrook, R. Gilson, M. Johnson, and C. A. Sabin. 2007. Risk of extensive virological failure to the three original antiretroviral drag classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study. Lancet 370:1923-1928.
32. Pilcher, C. D., H. C. Tien, J. J. Eron, Jr., P. L. Vernazza, S. Y. Leu, P. W. Stewart, L. E. Goh, and M. S. Cohen. 2004. Brief but efficient: acute HIV infection and the sexual transmission of HIV. J. Infect. Dis. 189:1785-1792.
33. Pillay, D., K. Bhaskaran, S. Jurriaans, M. Prins, B. Masquelier, F. Dabis, R. Gilford, C. Nielsen, C. Pedersen, C. Balotta, G. Rezza, M. Ortiz, C. de Mendoza, C. Kucherer, G. Poggensee, J. Gill, and K. Porter. 2006. The impact of transmitted drag resistance on the natural history of HIV infection and response to first-line therapy. AIDS 20:21-28.
34. Pillay, D., S. Taylor, and D. D. Richman. 2000. Incidence and impact of resistance against approved antiretroviral drags. Rev. Med. Virol. 10:231-253.
35. Quinn, T. C., M. J. Wawer, N. Sewankambo, D. Serwadda, C. Li, F. Wabwire-Mangen, M. O. Meehan, T. Lutalo, R. H. Gray, et al. 2000. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N. Engl. J. Med. 342:921-929.
36. Rambaut, A. 1996. Se-Al: Sequence alignment editor. Evolutionary Biology Group, Department of Zoology, University of Oxford, Oxford, United Kingdom. http://evolve.zoo.ox.ac.uk/.
37. Reeves, J. D., and A. J. Piefer. 2005. Emerging drug targets for antiretroviral therapy. Drags 65:1747-1766.
38. Ribeiro, R. M., and S. Bonhoeffer. 2000. Production of resistant HIV mutants during antiretroviral therapy. Proc. Natl. Acad. Sci. USA 97:7681-7686.
39. Richman, D. D. 2001. HIV chemotherapy. Nature 410:995-1001.
40. Schuurman, R., M. Nijhuis, R. van Leeuwen, P. Schipper, D. de Jong, P. Collis, S. A. Danner, J. Mulder, C. Loveday, C. Christopherson, et al. 1995. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drag-resistant virus populations in persons treated with lamivudine (3TC). J. Infect. Dis. 171:1411-1419.
41. SPREAD Programme. 2008. Transmission of drug-resistant HIV-1 in Europe remains limited to single classes. AIDS 22:625-635.
42. Suchard, M. A., R. E. Weiss, and J. S. Sinsheimer. 2001. Bayesian selection of continuous-time Markov chain evolutionary models. Mol. Biol. Evol. 18:1001-1013.
43. Swofford, D. L. 2001. PAUP 4.0: phylogenetic analysis using parsimony (and other methods). Sinauer Associates, Sunderland, MA.
44. Tang, J. W., and D. Pillay. 2004. Transmission of HIV-1 drag resistance. J. Clin. Virol. 30:1-10.
45. UK Collaborative Group on HIV Drug Resistance. 2007. Evidence of a decline in transmitted HIV-1 drug resistance in the United Kingdom. AIDS 21:1035-1039.
46. Vacca, J. P., B. D. Dorsey, W. A. Schleif, R. B. Levin, S. L. McDaniel, P. L. Darke, J. Zugay, J. C. Quintero, O. M. Blahy, E. Roth, et al. 1994. L-735, 524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc. Natl. Acad. Sci. USA 91:4096-4100.
47. van Maarseveen, N. M., A. M. Wensing, D. de Jong, M. Taconis, J. C. Borleffs, C. A. Boucher, and M. Nijhuis. 2007. Persistence of HIV-1 variants with multiple protease inhibitor (PI)-resistance mutations in the absence of PI therapy can be explained by compensatory fixation. J. Infect. Dis. 195: 399-409.
48. Whelan, S., and N. Goldman. 2001. A general empirical model of protein evolution derived from multiple protein families using a maximum-likelihood approach. Mol. Biol. Evol. 18:691-699.
49. Yang, Z. 1997. PAML: a program package for phylogenetic analysis by maximum likelihood. Comput. Appl. Biosci. 13:555-556.
50. Yang, Z. 1995. A space-time process model for the evolution of DNA sequences. Genetics 139:993-1005.
51. Yerly, S., V. von Wyl, B. Ledergerber, J. Boni, J. Schupbach, P. Burgisser, T. Klimkait, M. Rickenbach, L. Kaiser, H. F. Gunthard, and L. Perrin. 2007. Transmission of HIV-1 drag resistance in Switzerland: a 10-year molecular epidemiology survey. AIDS 21:2223-2229.